返回 Agenda
Session Chair(s)
Richard Stephen Geary, PHD
Senior Vice President, Drug Development
Ionis Pharmaceuticals, Inc., United States
Speaker(s)
Targeting APOC-III in Severe Hypertriglyceridemia
Walter Singleton, MD
Isis Pharmaceuticals Inc., United States
Chief Medical Officer
Clinical Trials of ALN-TTR02, an siRNA Therapeutic for Transthyretin Amyloidosis
Jared A. Gollob, MD
Alnylam Pharmaceuticals, Inc., United States
Vice President, Clinical Research
Isis CRPRx: Pharmacokinetics, Pharmacodynamics, Safety and Tolerability
Marshelle Smith Warren, MD
Isis Pharmaceuticals Inc., United States
Executive Director